<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02005029</url>
  </required_header>
  <id_info>
    <org_study_id>HM15105</org_study_id>
    <nct_id>NCT02005029</nct_id>
  </id_info>
  <brief_title>Erythromycin in Parkinson's Disease</brief_title>
  <official_title>Erythromycin in Parkinson's Disease: A Pilot Study of Its Effects on Levodopa Pharmacokinetics and Pharmacodynamics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Virginia Commonwealth University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Virginia Commonwealth University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Gastroparesis (slow stomach emptying) is a common feature of Parkinson's Disease. Levodopa
      (Sinemet), a common medication for Parkinson's Disease, can make gastroparesis worse.
      Gastroparesis effects how the levodopa is absorbed and used by the body. This study will
      explore the possibility of using Erythromycin, a drug commonly used (off label) for
      gastroparesis, along with levodopa to determine if there is improved levodopa absorption and
      motor function.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants will be required to make four visits for evaluation. Visit 1 is a screening
      visit, participants will receive the study drug or a placebo during visits 2 and 3, and visit
      4 is a follow up visit. Participants will provide blood and urine samples during the visits.
      Participants will also be required to complete questionnaires and a series of motor tests.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Gastric Emptying Time</measure>
    <time_frame>2 weeks, between visits 2 and 3</time_frame>
    <description>Mean gastric emptying time in minutes as measured by SmartPill</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Curve 0-4 Hours for Plasma Levodopa After Erythromycin Versus Placebo</measure>
    <time_frame>2 weeks, between visits 2 and 3</time_frame>
    <description>Mean Area under the Curve 0-4 hours for plasma levodopa after erythromycin versus placebo. Plasma samples were collected at the following times post-levodopa dose: 15, 30, 45, 60, 75, 90, 105, 120, 150, 180, 210, and 240 minutes.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>9-hole Peg Test Right Hand</measure>
    <time_frame>2 weeks, between visits 2 and 3</time_frame>
    <description>Change in motor function as assessed by 9-hole peg test for upper extremity manipulation/dexterity. This test measures the total time required to place and remove 9 holes in a pegboard. Each hand is tested separately.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>9-hole Peg Test Left Hand</measure>
    <time_frame>2 weeks, between visits 2 and 3</time_frame>
    <description>Change in motor function as assessed by 9-hole peg test for upper extremity manipulation/dexterity. This test measures the total time required to place and remove 9 holes in a pegboard. Each hand is tested separately.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Five Times Sit-to-stand Test</measure>
    <time_frame>2 weeks, between visits 2 and 3</time_frame>
    <description>Change in motor function as measured by Five times sit-to-stand test. This test measures the total time to complete 5 repetitions of sit to stand.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comfortable 20 Feet Gait Speed (CGS)</measure>
    <time_frame>2 weeks, between visits 2 and 3</time_frame>
    <description>Change in motor function as assessed by comfortable 20 feet gait speed (CGS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Timed up and go Test (TUAG) Comfortable Speed</measure>
    <time_frame>2 weeks, between visits 2 and 3</time_frame>
    <description>Change in motor function as assessed by timed up and go test (comfortable speed). This test measures the total time to stand from a chair, walk 10 feet, and return to sitting.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Timed up and go Test (TUAG) Fast Speed</measure>
    <time_frame>2 weeks, between visits 2 and 3</time_frame>
    <description>Change in motor function as assessed by timed up and go test (fast speed). This test measures the total time to stand from a chair, walk 10 feet, and return to sitting.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Dyskinesia</measure>
    <time_frame>2 weeks, between visits 2 and 3</time_frame>
    <description>Mean total AIMS (Abnormal Involuntary Movements Scale) score after receiving erythromycin minus mean total AIMS score after receiving placebo. The AIMS test has a total of twelve items rating involuntary movements of various areas of the patient's body. Ten of the items are rated on a five-point scale of severity from 0-4. The scale is rated from 0 (none), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe). Two of the items are not scored. Total score range is from 0 to 40. Higher scores represent more severe dyskinesia (a worse outcome).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MDS-UPDRS Part 3 (Movement Disorders Society- Unified Parkinson's Disease Rating Scale)</measure>
    <time_frame>2 weeks, between visits 2 and 3</time_frame>
    <description>Part 3 of this scale is a standardized physical assessment that quantifies the total burden of motor symptoms in Parkinson's disease patients. Each of the 18 items on the scale is rated from 0 (none, 1 (slight), 2 (mild), 3 (moderate) and 4 (severe). Scores range from 0-72. Higher scores represent a more severe burden of motor symptoms (a worse outcome).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Cmax of Plasma Levodopa After Erythromycin Versus Placebo</measure>
    <time_frame>2 weeks, between visits 2 and 3</time_frame>
    <description>Mean Cmax of plasma levodopa after erythromycin versus placebo. Plasma samples were collected at the following times post-levodopa dose: 15, 30, 45, 60, 75, 90, 105, 120, 150, 180, 210, and 240 minutes.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Parkinson's Disease</condition>
  <condition>Levodopa</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>One time IV dose of placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Erythromycin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One time IV dose of 100 mg Erythromycin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erythromycin</intervention_name>
    <arm_group_label>Erythromycin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects must have a definitive diagnosis of Parkinson's Disease (per United Kingdom
             brain bank criteria), Hoehn and Yahr stage 1-3,

          -  must exhibit unequivocal levodopa responsiveness

          -  must be able to distinguish between the &quot;off&quot; versus &quot;on&quot; state

          -  Subjects must be on a stable dose of levodopa for at least 28 days prior to enrollment
             and should be anticipated to maintain a stable dose throughout both study periods

          -  Subjects may be on concomitant therapy with Monoamine oxidase B inhibitors,
             entacapone, and amantadine, though the doses of these medications must have remained
             stable for at least 28 days prior to enrollment and must be expected to remain stable
             throughout both study periods.

        Exclusion Criteria:

          -  History of deep brain stimulation for Parkinson Disease

          -  History of ablative (tissue removal) surgery for Parkinson Disease

          -  Presence of dementia (MMSE&lt;25)

          -  Presence of active psychosis

          -  History of any chronic gastrointestinal diseases

          -  History of any prior gastrointestinal surgeries except for appendectomy,
             cholecystectomy, and hysterectomy

          -  Any gastrointestinal surgeries in the past 3 months

          -  Severe dysphagia (difficulty swallowing) to pills or food

          -  History of physiological or mechanical gastrointestinal obstruction

          -  History of strictures or fistulae (abnormal or narrow connections) along the
             gastrointestinal tract

          -  History of gastric bezoars (undigested mass)

          -  Allergy to wheat, soy, milk, or nuts

          -  Presence of portable electromechanical devices such as pacemaker, defibrillator, or
             infusion pump

          -  Female subjects who are pregnant or lactating

          -  Symptomatic orthostatic hypotension (low blood pressure)

          -  Diabetes

          -  Presence of symptomatic anemia

          -  Abnormal liver or kidney function

          -  Cardiac arrhythmia (past or present) or abnormal QT interval on entrance EKG

          -  Known hypersensitivity to any of the study drugs

          -  Subjects receiving certain medications during specified time frames
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leslie J Cloud, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Virginia Commonwealth University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Virginia Commonwealth University Parkinson's Center</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 18, 2013</study_first_submitted>
  <study_first_submitted_qc>December 3, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2013</study_first_posted>
  <results_first_submitted>October 3, 2016</results_first_submitted>
  <results_first_submitted_qc>December 15, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 3, 2017</results_first_posted>
  <last_update_submitted>December 15, 2016</last_update_submitted>
  <last_update_submitted_qc>December 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Parkinson's Disease</keyword>
  <keyword>Levodopa</keyword>
  <keyword>motor fluctuations</keyword>
  <keyword>gastroparesis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levodopa</mesh_term>
    <mesh_term>Erythromycin</mesh_term>
    <mesh_term>Erythromycin Estolate</mesh_term>
    <mesh_term>Erythromycin Ethylsuccinate</mesh_term>
    <mesh_term>Erythromycin stearate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Eighteen patients were screened for eligibility between April 2013 and June 2015 at the Virginia Commonwealth University Parkinson's and Movement Disorders Center.</recruitment_details>
      <pre_assignment_details>10 of 18 participants were randomized. Of those not randomized, 7 did not meet eligibility criteria and 1 was withdrawn by the principal investigator prior to randomization due to noncompliance with the protocol.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo First Then Erythromycin</title>
          <description>One time IV dose of placebo followed by 1 time IV dose of Erythromycin (after 2 week washout)</description>
        </group>
        <group group_id="P2">
          <title>Erythromycin Then Placebo</title>
          <description>One time IV dose of 100 mg Erythromycin followed by 1 time IV dose of placebo (after 2 week washout)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention (1 Day)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>participant withdrawn for noncompliance</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Washout (2 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second Intervention (1 Day)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo First Then Erythromycin</title>
          <description>One time IV dose of placebo followed by 1 time IV dose of Erythromycin (after 2 week washout)</description>
        </group>
        <group group_id="B2">
          <title>Erythromycin Then Placebo</title>
          <description>One time IV dose of 100 mg Erythromycin followed by 1 time IV dose of placebo (after 2 week washout)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.6" lower_limit="51" upper_limit="77"/>
                    <measurement group_id="B2" value="64.0" lower_limit="50" upper_limit="76"/>
                    <measurement group_id="B3" value="64.3" lower_limit="50" upper_limit="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Gastric Emptying Time</title>
        <description>Mean gastric emptying time in minutes as measured by SmartPill</description>
        <time_frame>2 weeks, between visits 2 and 3</time_frame>
        <population>Of the original ten participants; one participant's data was excluded due to symptomatic orthostasis which likely confounded her results, one participant was withdrawn early due to noncompliance, and four participants were unable to complete a SmartPill evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Erythromycin</title>
            <description>Mean gastric emptying time for participants receiving erythromycin</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Mean gastric emptying time for participants receiving placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Gastric Emptying Time</title>
          <description>Mean gastric emptying time in minutes as measured by SmartPill</description>
          <population>Of the original ten participants; one participant's data was excluded due to symptomatic orthostasis which likely confounded her results, one participant was withdrawn early due to noncompliance, and four participants were unable to complete a SmartPill evaluation.</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105" spread="66.5"/>
                    <measurement group_id="O2" value="180" spread="40.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.036</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Curve 0-4 Hours for Plasma Levodopa After Erythromycin Versus Placebo</title>
        <description>Mean Area under the Curve 0-4 hours for plasma levodopa after erythromycin versus placebo. Plasma samples were collected at the following times post-levodopa dose: 15, 30, 45, 60, 75, 90, 105, 120, 150, 180, 210, and 240 minutes.</description>
        <time_frame>2 weeks, between visits 2 and 3</time_frame>
        <population>Of the original ten participants; one participant's data was excluded due to symptomatic orthostasis which likely confounded her results, one participant was withdrawn early due to noncompliance, and one participant had undetectable plasma levodopa levels through out the study and was thus excluded from the pharmacokinetic analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Erythromycin</title>
            <description>Area under the curve 0-4 hours for plasma levodopa after erythromycin</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Area under the curve 0-4 hours for plasma levodopa after placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve 0-4 Hours for Plasma Levodopa After Erythromycin Versus Placebo</title>
          <description>Mean Area under the Curve 0-4 hours for plasma levodopa after erythromycin versus placebo. Plasma samples were collected at the following times post-levodopa dose: 15, 30, 45, 60, 75, 90, 105, 120, 150, 180, 210, and 240 minutes.</description>
          <population>Of the original ten participants; one participant's data was excluded due to symptomatic orthostasis which likely confounded her results, one participant was withdrawn early due to noncompliance, and one participant had undetectable plasma levodopa levels through out the study and was thus excluded from the pharmacokinetic analysis.</population>
          <units>ng/mL*min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="123237" spread="137561"/>
                    <measurement group_id="O2" value="103584" spread="106271"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Erythromycin:Placebo AUC ratio</param_type>
            <param_value>1.07</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0.43</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>9-hole Peg Test Right Hand</title>
        <description>Change in motor function as assessed by 9-hole peg test for upper extremity manipulation/dexterity. This test measures the total time required to place and remove 9 holes in a pegboard. Each hand is tested separately.</description>
        <time_frame>2 weeks, between visits 2 and 3</time_frame>
        <population>Of the original 10 participants, one participant's data was excluded due to symptomatic orthostasis which likely confounded her results and one participant was withdrawn early due to noncompliance.</population>
        <group_list>
          <group group_id="O1">
            <title>Erythromycin</title>
            <description>Mean time for right hand after erythromycin</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Mean time for right hand after placebo</description>
          </group>
        </group_list>
        <measure>
          <title>9-hole Peg Test Right Hand</title>
          <description>Change in motor function as assessed by 9-hole peg test for upper extremity manipulation/dexterity. This test measures the total time required to place and remove 9 holes in a pegboard. Each hand is tested separately.</description>
          <population>Of the original 10 participants, one participant's data was excluded due to symptomatic orthostasis which likely confounded her results and one participant was withdrawn early due to noncompliance.</population>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.36" spread="4.37"/>
                    <measurement group_id="O2" value="25.80" spread="4.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.65</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>9-hole Peg Test Left Hand</title>
        <description>Change in motor function as assessed by 9-hole peg test for upper extremity manipulation/dexterity. This test measures the total time required to place and remove 9 holes in a pegboard. Each hand is tested separately.</description>
        <time_frame>2 weeks, between visits 2 and 3</time_frame>
        <population>Of the original 10 participants, one participant's data was excluded due to symptomatic orthostasis which likely confounded her results and one participant was withdrawn early due to noncompliance.</population>
        <group_list>
          <group group_id="O1">
            <title>Erythromycin</title>
            <description>Mean time for right hand after erythromycin</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Mean time for right hand after placebo</description>
          </group>
        </group_list>
        <measure>
          <title>9-hole Peg Test Left Hand</title>
          <description>Change in motor function as assessed by 9-hole peg test for upper extremity manipulation/dexterity. This test measures the total time required to place and remove 9 holes in a pegboard. Each hand is tested separately.</description>
          <population>Of the original 10 participants, one participant's data was excluded due to symptomatic orthostasis which likely confounded her results and one participant was withdrawn early due to noncompliance.</population>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.36" spread="6.27"/>
                    <measurement group_id="O2" value="27.33" spread="6.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.18</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Five Times Sit-to-stand Test</title>
        <description>Change in motor function as measured by Five times sit-to-stand test. This test measures the total time to complete 5 repetitions of sit to stand.</description>
        <time_frame>2 weeks, between visits 2 and 3</time_frame>
        <population>Of the original 10 participants, one participant's data was excluded due to symptomatic orthostasis which likely confounded her results and one participant was withdrawn early due to noncompliance.</population>
        <group_list>
          <group group_id="O1">
            <title>Erythromycin</title>
            <description>Five times sit-to-stand for all participants receiving erythromycin</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Five times sit-to-stand for all participants receiving placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Five Times Sit-to-stand Test</title>
          <description>Change in motor function as measured by Five times sit-to-stand test. This test measures the total time to complete 5 repetitions of sit to stand.</description>
          <population>Of the original 10 participants, one participant's data was excluded due to symptomatic orthostasis which likely confounded her results and one participant was withdrawn early due to noncompliance.</population>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.09" spread="2.24"/>
                    <measurement group_id="O2" value="10.09" spread="2.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4405</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comfortable 20 Feet Gait Speed (CGS)</title>
        <description>Change in motor function as assessed by comfortable 20 feet gait speed (CGS)</description>
        <time_frame>2 weeks, between visits 2 and 3</time_frame>
        <population>Of the original 10 participants, one participant's data was excluded due to symptomatic orthostasis which likely confounded her results and one participant was withdrawn early due to noncompliance.</population>
        <group_list>
          <group group_id="O1">
            <title>Erythromycin</title>
            <description>Mean CGS for all participants receiving erythromycin</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Mean CGS for all participants receiving placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Comfortable 20 Feet Gait Speed (CGS)</title>
          <description>Change in motor function as assessed by comfortable 20 feet gait speed (CGS)</description>
          <population>Of the original 10 participants, one participant's data was excluded due to symptomatic orthostasis which likely confounded her results and one participant was withdrawn early due to noncompliance.</population>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.26" spread="0.44"/>
                    <measurement group_id="O2" value="4.10" spread="0.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6011</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Timed up and go Test (TUAG) Comfortable Speed</title>
        <description>Change in motor function as assessed by timed up and go test (comfortable speed). This test measures the total time to stand from a chair, walk 10 feet, and return to sitting.</description>
        <time_frame>2 weeks, between visits 2 and 3</time_frame>
        <population>Of the original 10 participants, one participant's data was excluded due to symptomatic orthostasis which likely confounded her results and one participant was withdrawn early due to noncompliance.</population>
        <group_list>
          <group group_id="O1">
            <title>Erythromycin</title>
            <description>TUAG (comfortable speed) after erythromycin</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>TUAG (comfortable speed) after placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Timed up and go Test (TUAG) Comfortable Speed</title>
          <description>Change in motor function as assessed by timed up and go test (comfortable speed). This test measures the total time to stand from a chair, walk 10 feet, and return to sitting.</description>
          <population>Of the original 10 participants, one participant's data was excluded due to symptomatic orthostasis which likely confounded her results and one participant was withdrawn early due to noncompliance.</population>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.67" spread="1.33"/>
                    <measurement group_id="O2" value="8.26" spread="1.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8923</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Timed up and go Test (TUAG) Fast Speed</title>
        <description>Change in motor function as assessed by timed up and go test (fast speed). This test measures the total time to stand from a chair, walk 10 feet, and return to sitting.</description>
        <time_frame>2 weeks, between visits 2 and 3</time_frame>
        <population>Of the original 10 participants, one participant's data was excluded due to symptomatic orthostasis which likely confounded her results and one participant was withdrawn early due to noncompliance.</population>
        <group_list>
          <group group_id="O1">
            <title>Erythromycin</title>
            <description>TUAG (fast speed) after erythromycin</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>TUAG (fast speed) after placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Timed up and go Test (TUAG) Fast Speed</title>
          <description>Change in motor function as assessed by timed up and go test (fast speed). This test measures the total time to stand from a chair, walk 10 feet, and return to sitting.</description>
          <population>Of the original 10 participants, one participant's data was excluded due to symptomatic orthostasis which likely confounded her results and one participant was withdrawn early due to noncompliance.</population>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.79" spread="0.927"/>
                    <measurement group_id="O2" value="6.85" spread="1.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.832</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Dyskinesia</title>
        <description>Mean total AIMS (Abnormal Involuntary Movements Scale) score after receiving erythromycin minus mean total AIMS score after receiving placebo. The AIMS test has a total of twelve items rating involuntary movements of various areas of the patient's body. Ten of the items are rated on a five-point scale of severity from 0â€“4. The scale is rated from 0 (none), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe). Two of the items are not scored. Total score range is from 0 to 40. Higher scores represent more severe dyskinesia (a worse outcome).</description>
        <time_frame>2 weeks, between visits 2 and 3</time_frame>
        <population>Of the original 10 participants, one participant's data was excluded due to symptomatic orthostasis which likely confounded her results and one participant was withdrawn early due to noncompliance.</population>
        <group_list>
          <group group_id="O1">
            <title>Erythromycin</title>
            <description>AIMS after receiving erythromycin</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>AIMS after receiving placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Dyskinesia</title>
          <description>Mean total AIMS (Abnormal Involuntary Movements Scale) score after receiving erythromycin minus mean total AIMS score after receiving placebo. The AIMS test has a total of twelve items rating involuntary movements of various areas of the patient's body. Ten of the items are rated on a five-point scale of severity from 0â€“4. The scale is rated from 0 (none), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe). Two of the items are not scored. Total score range is from 0 to 40. Higher scores represent more severe dyskinesia (a worse outcome).</description>
          <population>Of the original 10 participants, one participant's data was excluded due to symptomatic orthostasis which likely confounded her results and one participant was withdrawn early due to noncompliance.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.875" spread="1.458"/>
                    <measurement group_id="O2" value="0.375" spread="1.061"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1546</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MDS-UPDRS Part 3 (Movement Disorders Society- Unified Parkinson's Disease Rating Scale)</title>
        <description>Part 3 of this scale is a standardized physical assessment that quantifies the total burden of motor symptoms in Parkinson's disease patients. Each of the 18 items on the scale is rated from 0 (none, 1 (slight), 2 (mild), 3 (moderate) and 4 (severe). Scores range from 0-72. Higher scores represent a more severe burden of motor symptoms (a worse outcome).</description>
        <time_frame>2 weeks, between visits 2 and 3</time_frame>
        <population>One participant's data was excluded due to symptomatic orthostasis which likely confounded her results and one participant was withdrawn early due to noncompliance.</population>
        <group_list>
          <group group_id="O1">
            <title>Erythromycin</title>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>MDS-UPDRS Part 3 (Movement Disorders Society- Unified Parkinson's Disease Rating Scale)</title>
          <description>Part 3 of this scale is a standardized physical assessment that quantifies the total burden of motor symptoms in Parkinson's disease patients. Each of the 18 items on the scale is rated from 0 (none, 1 (slight), 2 (mild), 3 (moderate) and 4 (severe). Scores range from 0-72. Higher scores represent a more severe burden of motor symptoms (a worse outcome).</description>
          <population>One participant's data was excluded due to symptomatic orthostasis which likely confounded her results and one participant was withdrawn early due to noncompliance.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Before or &quot;off&quot; levodopa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.75" spread="13.26"/>
                    <measurement group_id="O2" value="25.37" spread="11.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After or &quot;on&quot; levodopa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.13" spread="11.48"/>
                    <measurement group_id="O2" value="16.50" spread="8.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0314</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>4.75</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>5.00</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>Mean difference in &quot;on&quot; score versus &quot;off&quot; score from the MDS UPDRS Part 3 on day of erythromycin minus the mean difference in 'on&quot; score versus &quot;off&quot; score on day of placebo.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Cmax of Plasma Levodopa After Erythromycin Versus Placebo</title>
        <description>Mean Cmax of plasma levodopa after erythromycin versus placebo. Plasma samples were collected at the following times post-levodopa dose: 15, 30, 45, 60, 75, 90, 105, 120, 150, 180, 210, and 240 minutes.</description>
        <time_frame>2 weeks, between visits 2 and 3</time_frame>
        <population>Of the original ten participants; one participant's data was excluded due to symptomatic orthostasis which likely confounded her results, one participant was withdrawn early due to noncompliance, and one participant had undetectable plasma levodopa levels throughout the study and was thus excluded from the pharmacokinetic analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Erythromycin</title>
            <description>Cmax of plasma levodopa after erythromycin</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Cmax of plasma levodopa after placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Cmax of Plasma Levodopa After Erythromycin Versus Placebo</title>
          <description>Mean Cmax of plasma levodopa after erythromycin versus placebo. Plasma samples were collected at the following times post-levodopa dose: 15, 30, 45, 60, 75, 90, 105, 120, 150, 180, 210, and 240 minutes.</description>
          <population>Of the original ten participants; one participant's data was excluded due to symptomatic orthostasis which likely confounded her results, one participant was withdrawn early due to noncompliance, and one participant had undetectable plasma levodopa levels throughout the study and was thus excluded from the pharmacokinetic analysis.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1267" spread="1012"/>
                    <measurement group_id="O2" value="1395" spread="1015"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Erythromycin:Placebo Cmax ratio</param_type>
            <param_value>0.83</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0.24</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year, 10 months</time_frame>
      <desc>Participants were followed from the beginning to the end of their active participation or the resolution of any adverse events.</desc>
      <group_list>
        <group group_id="E1">
          <title>Erythromycin</title>
          <description>Participants who received a one time dose of IV erythromycin</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Participants who received a one time dose of placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>symptomatic orthostasis</sub_title>
                <description>One participant developed symptomatic orthostatic hypotension during both her erythromycin and placebo dosing days. This resolved within a few minutes following sips of water and rest.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>diarrhea</sub_title>
                <description>One participant developed a single episode of loose stool during her erythromycin dosing day. No intervention was necessary.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>transaminitis</sub_title>
                <description>One participant had a mild transaminitis identified at his final safety visit (after placebo dosing day). This was thought to be due to over use of pain medication for an acute back injury. This resolved after stopping pain medication.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>akathisia</sub_title>
                <description>One participant developed self limited akathisia after taking levodopa during his erythromycin dosing day. This resolved after a few minutes with no intervention.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>possible hematuria</sub_title>
                <description>One participant had trace hematuria on urinalysis from his final safety visit (occurring after his erythromycin dosing day). Urinalysis was repeated by primary care provider one day later and was normal.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>An overall limitation was the small sample size.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Leslie Cloud</name_or_title>
      <organization>Virginia Commonwealth University</organization>
      <phone>804-662-5304</phone>
      <email>leslie.cloud@vcuhealth.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

